182 related articles for article (PubMed ID: 12806638)
1. Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?
Cuffari C; Lichtenstein GR
Gastroenterology; 2003 Jun; 124(7):1988-90. PubMed ID: 12806638
[No Abstract] [Full Text] [Related]
2. Monoclonal antibody therapy for Crohn's disease.
Selby W
Intern Med J; 2001 Mar; 31(2):73-4. PubMed ID: 11480481
[No Abstract] [Full Text] [Related]
3. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
[TBL] [Abstract][Full Text] [Related]
4. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Loftus EV
Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
[No Abstract] [Full Text] [Related]
5. [Maintenance treatment by anti-tumor necrosis factor monoclonal antibody in Crohn's disease--long-term effects and safety].
Matsui T
Nihon Shokakibyo Gakkai Zasshi; 2008 May; 105(5):649-58. PubMed ID: 18460853
[No Abstract] [Full Text] [Related]
6. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of infliximab in Crohn's disease.
Hanauer SB
N Engl J Med; 2003 May; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
[No Abstract] [Full Text] [Related]
8. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
[TBL] [Abstract][Full Text] [Related]
9. Systemic amyloidosis with Crohn's disease treated with infliximab.
Park YK; Han DS; Eun CS
Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971
[No Abstract] [Full Text] [Related]
10. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
Vermeire S; Noman M; Van Assche G; Baert F; Van Steen K; Esters N; Joossens S; Bossuyt X; Rutgeerts P
Gastroenterology; 2003 Jul; 125(1):32-9. PubMed ID: 12851868
[TBL] [Abstract][Full Text] [Related]
11. Discussion on predictors of response to infliximab in patients with Crohn's disease.
Hommes D
Gastroenterology; 2003 Jun; 124(7):2002-3. PubMed ID: 12812196
[No Abstract] [Full Text] [Related]
12. Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for Crohn's disease.
Matsuoka K; Kanai T
Digestion; 2013; 88(1):17-9. PubMed ID: 23797247
[TBL] [Abstract][Full Text] [Related]
13. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
14. [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001].
Domènech E; Esteve-Comas M; Gomollón F; Hinojosa J; Obrador A; Panés J; Gassull MA;
Gastroenterol Hepatol; 2002 Mar; 25(3):162-9. PubMed ID: 11864540
[No Abstract] [Full Text] [Related]
15. Time of infliximab therapy initiation and dose escalation in Crohn's disease.
Lam MC; Lee T; Atkinson K; Bressler B
World J Gastroenterol; 2014 Jan; 20(1):214-8. PubMed ID: 24415874
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis induced by infliximab in a patient suffering from Crohn's disease.
Manni E; Barachini P
Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
Lamireau T; Cézard JP; Dabadie A; Goulet O; Lachaux A; Turck D; Maurage C; Morali A; Sokal E; Belli D; Stoller J; Cadranel S; Ginies JL; Viola S; Huet F; Languepin J; Lenaerts C; Bury F; Sarles J;
Inflamm Bowel Dis; 2004 Nov; 10(6):745-50. PubMed ID: 15626892
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha antagonists for the treatment of Crohn's disease.
Kam LY; Targan SR
Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506
[TBL] [Abstract][Full Text] [Related]
19. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception.
Angelucci E; Cocco A; Viscido A; Caprilli R
Inflamm Bowel Dis; 2008 Mar; 14(3):435-6. PubMed ID: 18050300
[No Abstract] [Full Text] [Related]
20. Basiliximab and infliximab for the treatment of steroid-refractory Crohn's disease.
Price M; Probert CS; Creed T
Am J Gastroenterol; 2008 Oct; 103(10):2665. PubMed ID: 18855871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
